| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-05-23 | abemaciclib (LY2835219) | non-small cell lung cancer (NSCLC) | 3 | Eli Lilly (USA - IN) | Cancer - Oncology |
| 2014-05-23 | tofacitinib | psoriasis | 3 | Pfizer (USA - NY) | Autoimmune diseases - Dermatological diseases |
| 2014-05-22 | artificial pancreas | diabetes |
Universitat Politècnica de València, the Instituto de Investigación Sanitaria (INCLIVA) of the Hospital Clínico Universitario de Valencia (Spain), Hospital Clínic de Barcelona (Spain) Polytechnic School of the Universitat de Girona (Spain) | Metabolic diseases | |
| 2014-05-21 | Resokine IV | 1 | aTyr Pharma (USA) | Rare diseases | |
| 2014-05-21 | RNAi therapeutics targeting aminolevulinic acid synthase-1 (ALAS-1) | hepatic porphyrias, including acute intermittent porphyria ( |
preclinical | Alnylam Pharmaceuticals (USA - MA) | Rare diseases |
| 2014-05-20 | GS-5806 | respiratory syncytial virus infection |
2 | Gilead (USA) | Infectious diseases |
| 2014-05-20 | ISIS-PKK Rx | hereditary angioedemia (HAE) |
1 | Isis Pharmaceuticals (USA) | Rare diseases |
| 2014-05-19 | ofatumumab | diffuse large B-cell lymphoma (DLBCL) |
3 | Genmab (Denmark) GSK (UK) | Cancer Oncology |
| 2014-05-19 | veliparib (ABT-888) | metastatic breast cancer | 3 | Abbvie (USA - IL) | Cancer - Oncology |
| 2014-05-19 | Clostridium difficile vaccine (ACAM-CDIFF™) | prevention of Clostridium difficile infection |
2 | Sanofi Pasteur (France) | Infectious diseases |
| 2014-05-16 | Vesimune (TMX-101) | CIS (carcinoma in situ) in the bladder |
2 | Telormedix (Switzerland) | Cancer- Oncology |
| 2014-05-15 | PSX1002 | moderate to severe chronic obstructive pulmonary disease (COPD) |
2 | Prosonix (UK) | Respiratory diseases |
| 2014-05-14 | nivolumab | advanced melanoma | 1b | BMS (USA - NY) | Cancer - Oncology |
| 2014-05-13 | saxagliptin/dapagliflozin combination | type 2 diabetes |
3 | AstraZeneca (UK) | Metabolic diseases |
| 2014-05-13 | darapladib | treatment of adults following an acute coronary syndrome |
3 | GSK (UK) | Cardiovascular diseases |
| 2014-05-13 | AMA0076 | 2 | Amakem Therapeutics (Belgium) | ||
| 2014-05-13 | evolocumab | patients with high cholesterol | 3 | Amgen (USA - CA) | Cardiovascular diseases |
| 2014-05-12 | aganirsen | corneal neovascularisation due to inflammation (keratitis) |
3 | Gene Signal (Switzerland) | Ophtalmological diseases |
| 2014-05-12 | mavrilimumab | rheumatoid arthritis |
2b | AstraZeneca (UK) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2014-05-12 | sifalimumab | moderate/severe systemic lupus erythematosus |
2b | AstraZeneca (UK) | Autoimmune diseases |
